Isis Pharmaceuticals, Inc.

Phenex Pharmaceuticals Ag

Phenix Pharmaceuticals Ag

Ronnie C Hanecak

Kevin P Anderson

Chikateru Nozaki

David J Ecker

Jacqueline R Wyatt

Thomas W Bruice

Timothy A Vickers

Vickie L Brown-Driver

John S Kiely

Claus Kremoser

Fukusaburo Hamada

Elena Dneprovskaia

Hiroshi Nakatake

Ulrich Deuschle

Tsukasa Nishihara

Kerstin Otte

Tatsuo Eto

Ulrike Bauer

Zach Cheruvallath

Kazuya Hoshiko

Shinichi Furukawa

Tim Gahman

Kristina Giegrich

Normand Hébert

Ingo Kober

Manfred Kögl

Harald Kranz

Matthew Lee

Carlton Sage

Manish Sud

C Frank Bennett

Walter F Lima

Peter W Davis

Ming-Yi Chiang

Susan M Freier

Phillip Dan Cook

Stanley T Crooke

Kenneth G Draper

Yogesh S Sanghvi

Christopher K Mirabelli

Shoji Furusako

Jean Louis Imbach

F Andrew Dorr

Shoji Furasako

T Jesse Kwoh

The invention provides compounds according to the general formula () which bind to the NRHreceptor and act as agonists, antagonists or mixed agonists/antagonists of the NRHreceptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

FXR NR1H4 nuclear receptor binding compounds

Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.

Modulation of telomere length by oligonucleotides having a G-core sequence

The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.

NR1H4 nuclear receptor binding compounds

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

Compositions and methods for treatment of hepatitis C virus-associated diseases

The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

Compositions and methods for treatment of Hepatitis C virus-associated diseases

Oligonucleotides having a conserved G4 core sequence

Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled oligomers are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.

Methods for synthetic unrandomization of oligomer fragments

Synthetic unrandomization of oligomer fragments

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

Oligonucleotide therapies for modulating the effects of herpes viruses

Growing community of inventors

San Clemente, CA, United States of America

Ronnie C Hanecak